Cardiology and Cardiovascular Medicine

Journal Information
EISSN : 25729292
Current Publisher: Fortune Journals (10.26502)
Total articles ≅ 139

Latest articles in this journal

Cardiology and Cardiovascular Medicine; doi:10.26502/fccm

Journal Cardiology and Cardiovascular Medicine aims to get good Impact factor, indexing in SCI, Scopus, PubMed, ESCI, Clarivate Analytics. Cardiology Journals, Cardiovascular medicine journals, heart journals
Lisete Lopes, Pedro A. Sousa, Helena Andrade, Dina Rodrigues, Joao Bernardo, Luis Elvas, Antonio . Pires
Cardiology and Cardiovascular Medicine, Volume 4, pp 79-86; doi:10.26502/fccm.92920105

Hypertrophic cardiomyopathy is the most common heritable cardiomyopathy, being the most frequent cause of sudden cardiac death in the young. Although sudden cardiac death risk stratification criteria have been validated for adults, its application is not recommended in a pediatric population. After considering risks and benefits, choosing the ideal candidate for an implantable cardioverter defibrillator (ICD) for primary prevention purposes still remains a challenge in a child with hypertrophic cardiomyopathy. In children, major issues concerning transvenous ICDs are those related to the lead implantation and the increased risk of systemic infections at mid-long term. With these in mind, it would appear that a subcutaneous ICD, in this population group, is an alternative to be considered. This case regarding a 30Kg, an 8-year-old child with hypertrophic cardiomyopathy highlights the difficulties in sudden cardiac death risk stratification, raises the questions related to which type of ICD to implant and illustrates the feasibility of a subcutaneous ICD in this particular setting.
Zeynep Ulutas, Hasan Ata Bolayir
Cardiology and Cardiovascular Medicine, Volume 4, pp 118-129; doi:10.26502/fccm.92920110

Background: Despite the fact that serglycin takes a crucial part in the inflammatory status, the correlation between the coronary artery disease (CAD) severity in subjects having non-ST segment elevation myocardial infarction (NSTEMI) and serglycin is still unknown. Methods: A total of 129 participants, including 90 NSTEMI subjects and 39 healthy controls, were included in the present research prospectively. The patient group was separated into two groups as subjects with a high SYNTAX score, which was equal to or higher than 32 (40 subjects), and subjects with a low SYNTAX score, which was lower than 32 (50 subjects). The enzyme-linked immunosorbent assay test was utilized to measure serglycin level from the collected blood serum samples. Results: A considerably higher serum serglycin level (17.2±3.4 ng/mL) was determined in NSTEMI subjects having the high SYNTAX score in comparison with NSTEMI subjects having the low SYNTAX score (11.4±2.1 ng/mL) and the control group (7.9±2.7 ng/mL). The serglycin cut-off value to predict the high SYNTAX score as a result of receiver-operating characteristic curve analysis was identified as 14.8 ng/mL, with a sensitivity of 67% and a specificity of 58%. Serglycin independently predicted the high SYNTAX score with an odds ratio of 0.999, a confidence interval of 95% (0.998–1.000), and p=0.007. Conclusion: Serglycin may represent a possible blood sample value in order to predict the CAD severity in NSTEMI subjects.
Gentian Denas, Nicola Gennaro, Eliana Ferroni, Ugo Fedeli, Giacomo Zoppellaro, Maria Chiara Corti, And Vittorio Pengo
Cardiology and Cardiovascular Medicine, Volume 4, pp 66-75; doi:10.26502/fccm.92920103

Aim: The use of oral anticoagulant drugs in patients with atrial fibrillation and one non-gender related risk factors is challenging. We compared the efficacy and safety of DOACs vs VKAs in low risk patients. Methods: We performed a population-based retrospective cohort study in anticoagulation-naïve atrial fibrillation patients. The cohort was identified, characterized and followed-up using data from administrative claims, drug prescriptions archive, and regional inpatient and discharge register. Event-rates were assessed using as treated analysis. Hazard ratios (HR) of stroke and major bleeding were estimated by Cox regression analysis. Results: Overall, we identified 1829 patients treated with DOACs and 6083 patients treated with VKAs, that accumulated 2097 and 4681 person-years of follow up, respectively. Half of patients were in the 65-75 age group, while almost 38% were female. Stroke rates were lower with DOACs as compared to VKAs: 0.14% person-years versus 0.28% person-years (HR 0.50, 95%CI 0.14–1.74). Major bleeding (0.81% person-years versus 1.09% person-years (HR 0.80, 95%CI 0.46–1.40)) and intracranial hemorrhage (0.33% person-years versus 0.42% person-years (HR 0.85, 95%CI 0.36–2.04) were also lower with DOACs. Mortality rate with DOACs was 1.2% person-years and 1.1 person-years with VKA (HR 1.21, 95%CI 0.74-1.96) mostly driven by death from cancer in the DOACs group. Conclusions: In low risk patients with atrial fibrillation, there is a benefit (although non-significant) with DOACs as compared to VKAs. Other studies are required to directly test this finding.
Emily M Williams, Tara N Daming, Sarah Hostetter, Karen Florio, Anna Grodzinsky, John Lee, Anthony Magalski, Valerie Rader, Laura Schmidt
Cardiology and Cardiovascular Medicine, Volume 4, pp 414-417; doi:10.26502/fccm.92920138

Aortic stenosis provides a unique management challenge during pregnancy and has historically been associated with a high maternal mortality risk. We describe our experience with pregnancies in patients with aortic stenosis at a single center over a 13 year period. When managed by an experienced, multidisciplinary, cardio-obstetrics team, these pregnancies are more likely to reach term with good outcomes.
Tarso A. D. Accorsi, Antonio F. B. De Azevedo Filho, Bruna R. S. Matuck, Mariana P. Lopes, Italo M. Ferreira, Mauricio R. Mocha, Joao R. C. Fernandes, Matheus De O. L. Ribeiro, Marcelo Kirschbaum, Fernando F. Ribas, et al.
Cardiology and Cardiovascular Medicine, Volume 4; doi:10.26502/fccm.92920133

Houda Nassih, Karima El Fakiri, Rabiy El Qadiry, Aicha Bourrahouat, Imane Ait Sab
Cardiology and Cardiovascular Medicine, Volume 4, pp 428-431; doi:10.26502/fccm.92920140

Administration of chloroquine with azithromycin for the treatment of coronavirus disease 2019 (COVID-19) carries increased risk of corrected QT interval (QTc) prolongation and cardiac arrhythmias. But it is difficult to identify the real cause of QTc prolongation when two or more risk factors are gathered. This was the case of our female patient presenting with QTc prolongation after starting chloroquine and azithromycin.
Priyanka Parajuli, Manjari Rani Regmi, Odalys Estefania Lara-Garcia, Ruby Maini, Mukul Bhattarai, Alan Deckard, Abhishek Kulkarni
Cardiology and Cardiovascular Medicine, Volume 4, pp 268-277; doi:10.26502/fccm.92920123

Cardiac troponin (cTn) is the preferred blood test utilized in the evaluation of acute coronary syndrome (ACS). Elevated cTn represents the presence of myocardial injury but not the cause. As new high sensitivity troponin assays become available, subtle cardiac injuries are being detected. The number of patients encountered with elevated troponin have therefore increased. It is now understood that non-coronary diseases can lead to elevated troponin. There are no specific management guidelines for patients with elevated troponin without a concomitant ACS. Treatment of underlying medical conditions remains the cornerstone of therapy in such patients. Therefore, differentiating elevated troponin secondary to ACS versus non-ACS causes is paramount in order to provide timely and appropriate intervention. In this paper, we discuss a series of cases presenting with elevated troponin, explore non-ACS troponin-elevating conditions along with their underlying pathophysiology, and provide a simple approach to determine the need for cardiology consultation.
Cardiology and Cardiovascular Medicine, Volume 4, pp 283-291; doi:10.26502/fccm.92920125

The 2019 coronavirus pandemic (COVID-19), caused by SARS-CoV-2, has affected 5,701,337 individuals globally and accounted for 357,688 deaths as of May 2020. While much of the focus has been on systemic inflammation and pulmonary complications, including interstitial pneumonia and acute respiratory distress syndrome (ARDS), cardiovascular complications related to COVID-19 can also result in severe morbidity and mortality. Mortality for acute myocardial infarction in ARDS caused by SARS-CoV-2 accounts for 2.6%, with risk factors including older age, hypertension, diabetes mellitus and previous cardiovascular events. In approximately 5-25% of hospitalized COVID-19 cases, elevations in cardiac Troponin have been reported. This biomarker appears to correlate with disease severity and poorer prognosis. The pathophysiology behind acute myocardial injury is complex and includes variable degrees of type I and type II myocardial infarction, with a wide range of coronary artery appearances on angiography. This pandemic has disrupted several protocols of care for emergency cardiac conditions. This has led to clinicians relying on fibrinolysis to a much greater extent in the management of acute coronary syndrome, as opposed to primary Percutaneous Coronary Intervention (PCI).
Gaia Cattadori, Carlo Vignati, Alice Bonomi, Massimo Mapelli, Susanna Sciomer, Mauro Pepi, Claudio Tondo, Giuseppe Ambrosio, Silvia Di Marco, Massimo Baravelli, et al.
Cardiology and Cardiovascular Medicine, Volume 4, pp 386-395; doi:10.26502/fccm.92920135

Objectives and Background: Hemodynamic changes at rest and during exercise in heart failure (HF) after cardiac resynchronization therapy (CRT) are still undefined. Methods: In 93 HF patients, before and 8 ± 3 months after CRT, we assessed clinical conditions, ECG and standard echocardiography and we performed a maximal cardiopulmonary exercise test with non-invasive measurement of cardiac output (CO) by inert gas rebreathing method. Results: At rest, CRT shortened QRS and improved NYHA class and left ventricular ejection fraction (LVEF), but not CO and stroke volume (SV). On average, at peak exercise, a significant improvement of oxygen uptake (VO2) (from 13.8 ± 3.8 ml/min/kg to 14.9 ± 4.6, p
Back to Top Top